Hirata Y, Tomita M, Takata S, Fujita T
Biochem Biophys Res Commun. 1985 Nov 15;132(3):1079-87. doi: 10.1016/0006-291x(85)91917-5.
Specific binding sites for vasoactive intestinal peptide (VIP), a potent vasodilatory polypeptide, and its effect on formation of intracellular cyclic AMP levels were studied in cultured vascular smooth muscle cells (VSMC) from rat aorta. Specific binding of 125I-labeled-VIP to cultured VSMCs was time- and temperature-dependent. Scatchard analysis of binding studies suggested the presence of two classes of high and low affinity binding sites for VIP; the apparent Kd and the number of maximal binding capacity were approximately 8 X 10(-9) M and 60,000 sites/cell (high-affinity sites) and approximately 4 X 10(-8) M and 140,000 sites/cell (low-affinity sites), respectively. Unlabeled VIP competitively inhibited the binding of 125I-labeled-VIP to its binding sites, whereas neither peptides structurally related to VIP, nor other vasoactive substances affected the binding. VIP stimulated formation of intracellular cyclic AMP in cultured VSMCs in a dose-dependent manner; the stimulatory effect of VIP on cyclic AMP formation was not blocked by propranolol and was additive with isoproterenol. The present study first demonstrates the presence of specific receptors for VIP in VSMCs functionally coupled to adenylate cyclase system. It is suggested that VIP exerts its vasodilatory effect through its specific receptors distinct from beta-adrenergic receptors.
研究了强效血管舒张多肽血管活性肠肽(VIP)的特异性结合位点及其对大鼠主动脉培养血管平滑肌细胞(VSMC)细胞内环磷酸腺苷(cAMP)水平形成的影响。125I标记的VIP与培养的VSMC的特异性结合具有时间和温度依赖性。结合研究的Scatchard分析表明,存在两类VIP的高亲和力和低亲和力结合位点;表观解离常数(Kd)和最大结合容量分别约为8×10(-9)M和60,000个位点/细胞(高亲和力位点)以及约4×10(-8)M和140,000个位点/细胞(低亲和力位点)。未标记的VIP竞争性抑制125I标记的VIP与其结合位点的结合,而与VIP结构相关的肽或其他血管活性物质均不影响该结合。VIP以剂量依赖性方式刺激培养的VSMC中细胞内cAMP的形成;VIP对cAMP形成的刺激作用不受普萘洛尔的阻断,且与异丙肾上腺素具有相加作用。本研究首次证明VSMC中存在与腺苷酸环化酶系统功能偶联的VIP特异性受体。提示VIP通过其不同于β-肾上腺素能受体的特异性受体发挥血管舒张作用。